Pharmaceutical Inspections and Compliance Essentials A pharmaceutical inspection is, in operational terms, a test of where the GxP boundary actually sits inside a manufacturing site. Inspectors read documents, walk the line, and ask one structural question: for each system that touches product quality, is the evidence proportional to the risk it carries? When AI/ML software enters that picture, the question doesn’t change — but the evidence the inspector expects does. This piece walks through what inspections actually look for, where AI software changes the conversation, and how teams stay inspection-ready without over-scoping non-GxP systems. What is a pharmaceutical inspection, in practice? Regulators — the FDA in the United States, the EMA and national competent authorities in the EU, PMDA in Japan — inspect to confirm three things: that the manufacturing process is the one that was approved, that quality controls work, and that records are reliable enough to reconstruct what happened to any batch. Pre-approval inspections gate market entry. Surveillance inspections, often unannounced, sample the steady state. The same logic applies to both: documentation first, observation second, and corrective action when the two diverge. The structural point is that an inspection isn’t a quality audit. It’s a check that the company’s own quality system catches problems before a regulator has to. That distinction matters when AI software is in the loop, because the question shifts from “does this model work?” to “does your quality system know when this model stops working?” Where AI software sits inside the inspection scope Not every system in a pharma facility is GxP-regulated. The boundary is set by impact on product quality, patient safety, or data integrity (the ALCOA+ principles inspectors lean on). A vision model that decides whether a vial is rejected on the line is squarely GxP. A demand-forecasting model that helps planning schedule a batch is generally not. A predictive maintenance model on a CIP skid is somewhere in between — it depends on whether its outputs change a GxP record or trigger a GxP action. Treating all AI software as if it requires the same validation as a GxP-critical system is a common over-scoping mistake. It’s expensive, it slows iteration, and — paradoxically — it can dilute the depth of evidence around the systems that actually matter. The TechnoLynx position on this is plain: scope first, then validate. We work through the GxP scope question for AI software before any validation effort is committed. What inspectors actually open when AI is in scope When an AI/ML system falls inside GxP scope, inspectors tend to ask for the same artefacts they’d ask for of any computerised system, plus a small set of AI-specific ones. Based on what we see across pharma engagements, the AI-specific additions cluster around four areas: Training data provenance — where the data came from, how it was labelled, what was excluded, and whether the training set is representative of the production distribution. Model lifecycle controls — when the model was last retrained, who authorised the retrain, and what change-control evidence accompanied it. Performance monitoring — how drift is detected, what thresholds trigger investigation, and how those investigations connect back to the deviation system. Human-in-the-loop boundaries — where the model’s output is decisive versus advisory, and how that distinction is enforced in the operator interface. None of this replaces classical GAMP 5 validation evidence (URS, FS, IQ/OQ/PQ as appropriate). It supplements it for the class of risk that deterministic software doesn’t carry: a model whose behaviour can drift between two inspections without anyone touching the code. GxP versus non-GxP — a quick decision surface The single most useful artefact a pharma team can keep current is a short table mapping each AI/ML system to its GxP status and the inspection evidence that follows. This is the heart of an A4 GxP Regulatory Scope Analysis, and it’s what we build with clients before any validation work starts. System role GxP status Inspection evidence expected Vision QC that rejects/accepts product on the line GxP Full CSV evidence, training data provenance, drift monitoring records, change control on retrain Lab informatics that records release data GxP CSV evidence, electronic-records (Part 11 / Annex 11) controls, audit trail review Predictive maintenance whose output triggers a GxP action GxP-adjacent Risk-based validation, documented HITL gate, change control on model updates Demand forecasting for planning Non-GxP Standard IT governance; no GxP validation required Document-classification assistant for QA reviewer Non-GxP if advisory; GxP if it makes the decision Depends on HITL design; document the boundary explicitly Two notes on reading this table. First, the expected evidence column is the floor, not the ceiling — a specific inspector or site may ask for more. Second, the GxP/non-GxP column is the company’s call, defended by its own scope analysis; inspectors test that judgement, they don’t make it for you. The deeper treatment of how this maps to ISPE’s GAMP framework sits in GxP compliance pharma requirements. Why inspection readiness is a continuous state Inspection readiness fails in predictable ways. Documentation that was current six months ago has drifted from how the line actually runs. Training records show staff trained on version 3 of an SOP while the line is operating to version 5. A model has been silently retrained by a vendor without a change-control entry. None of these are exotic failures — they’re the ordinary entropy of a manufacturing site between inspections. The countermeasure is structural, not heroic. Internal audits run on a schedule that’s tighter than the regulator’s. Change control is the only way a GxP system changes — including a model retrain, including a label-schema change, including a new training dataset. Deviation handling closes the loop: when a deviation involves an AI system, the investigation explicitly asks whether the model contributed and whether retraining or revalidation is required. In our experience across pharma engagements, the sites that handle inspections well are the ones where the AI systems are treated as ordinary GxP computerised systems with two additions: a documented retrain protocol and a documented drift-monitoring protocol. Everything else — Part 11 audit trails, electronic signatures, periodic review — is the same evidence base inspectors have asked for since Annex 11 was published. How global frameworks line up For a multi-site or multi-market operation, the inspection landscape is plural but mostly coherent. FDA expectations under 21 CFR Parts 210, 211, and Part 11 set one anchor. EU GMP and Annex 11 set another, with the EU AI Act now layering risk-classification language on top for systems that meet its criteria — covered in detail in Pharma’s EU AI Act Playbook. ICH guidelines (Q7, Q9, Q10) unify the underlying quality-system expectations. PIC/S inspection guidance gives inspectors a shared vocabulary across jurisdictions. The practical implication: build the evidence base to the strictest applicable standard, and the others follow. Where the AI-specific guidance is still evolving — ISPE’s GAMP AI guidance and the ISPE AI maturity model are the current reference points — companies that have a documented internal position are in a stronger inspection conversation than those waiting for full regulatory consensus. FAQ What does GxP compliance specifically require when the software is AI/ML rather than deterministic code? The classical GAMP 5 evidence — URS, functional spec, IQ/OQ/PQ scaled to risk — still applies. The additions for AI/ML are training data provenance, a documented retrain protocol under change control, drift monitoring with defined thresholds, and explicit human-in-the-loop boundaries. The principle is that everything that can change the system’s behaviour between inspections must be visible to the quality system. Which GxP rules apply to AI training data, models, and inference outputs? Training data and labels are GxP records when the resulting model is GxP-scope — they need provenance, controlled access, and retention. Models are configurable software under GAMP 5 categorisation, typically Category 4 or 5 depending on customisation. Inference outputs that drive a GxP decision (release, reject, deviation) are GxP records subject to Part 11 / Annex 11 electronic-records controls. How is a GxP-validated AI system kept compliant as the model retrains or drifts? Through two linked controls. Change control treats every retrain as a change requiring impact assessment, revalidation scope, and approval. Drift monitoring continuously tests the model against a held-out reference set and triggers investigation when performance crosses defined thresholds. A retrain that goes through change control with documented requalification is compliant; a silent retrain by a vendor is a finding. Where is the boundary between GxP and non-GxP usage of AI inside a pharma manufacturing workflow? The boundary is set by impact on product quality, patient safety, or data integrity. A model that decides product disposition is GxP. A model whose output is only consulted by humans before a human makes the GxP decision is generally non-GxP, provided the human-in-the-loop boundary is enforced in the interface and documented. Demand forecasting, internal analytics, and scheduling support are typically non-GxP. Scope analysis is the company’s call, defended by documentation. Which GxP roles (system owner, QA, validation lead) own AI-specific risks and how is that documented? System owner owns the model’s operational performance, including drift monitoring and retrain protocol execution. QA owns the change-control gate for model updates and the release of revalidation evidence. Validation lead owns the GAMP-categorisation decision and the validation plan. Data science contributes to training data provenance and model design but does not unilaterally release models into a GxP environment. This is documented in the validation plan and reflected in RACI for the system. How do ISPE’s GAMP AI guidance and the ISPE AI maturity model fit into an existing GxP programme? GAMP AI extends the existing GAMP 5 framework with AI-specific lifecycle controls — it doesn’t replace it. The maturity model is a self-assessment tool: it helps a quality organisation locate where its AI governance sits today and where it needs to be to operate GxP AI systems at scale. Neither is a regulation; both inform how a company defends its approach to inspectors. Where this fits The GxP boundary is the prerequisite question for every other compliance decision around AI in pharmaceutical manufacturing. Get that right, and validation depth, inspection evidence, and change-control discipline all follow proportionally. Get it wrong — by over-scoping non-GxP systems or under-scoping ones that actually drive product decisions — and the inspection conversation gets harder than it needs to be. The failure mode worth naming: a vision QC model retrained quarterly by a vendor with no entry in the site’s change-control log. The model still performs; the audit trail does not. That’s the gap an A4 GxP Regulatory Scope Analysis is designed to close before an inspector finds it.
